Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

20.94USD
8:11pm BST
Change (% chg)

$0.62 (+3.05%)
Prev Close
$20.32
Open
$20.25
Day's High
$20.97
Day's Low
$19.97
Volume
198,820
Avg. Vol
578,570
52-wk High
$53.90
52-wk Low
$11.50

Ivers-Read, Gillian 

Dr. Gillian C. Ivers-Read is Executive Vice President - Technical Operations, Chief Regulatory Officer of the Company. Ms. Ivers-Read served as Executive Vice President, Development Operations at Pharmion Corporation (acquired in 2008), beginning in 2002. From 1996 to 2001, Ms. Ivers-Read held various regulatory positions with Hoechst Marion Roussel and its successor, Aventis Pharmaceuticals, Inc., where she most recently held the position of Vice President, Global Regulatory Affairs. From 1994 to 1996, Ms. Ivers-Read was Vice President, Development and Regulatory Affairs for Argus Pharmaceuticals, and from 1984 to 1994, she served as a regulatory affairs director for Marion Merrell Dow. Ms. Ivers-Read received a B.Sc. in pharmacology from University College London.

Basic Compensation

Total Annual Compensation, USD 661,219
Restricted Stock Award, USD 683,100
Long-Term Incentive Plans, USD --
All Other, USD 1,039,560
Fiscal Year Total, USD 2,383,880

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. James Barrett

533,329

Patrick Mahaffy

8,726,480

Daniel Muehl

1,861,090

Gillian Ivers-Read

2,383,880

Lindsey Rolfe

2,429,680

Robert Azelby

--
As Of  31 Dec 2017